




RealRate

PHARMACEUTICAL 2020

Xenon Pharmaceuticals Inc.
Rank 117 of 362



XENON



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of Xenon Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xenon Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 174% points. The greatest weakness of Xenon Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 46% points.

The company's Economic Capital Ratio, given in the ranking table, is -67%, being 236% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	144,866
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	43,379
Liabilities, Non-Current	12,341
Other Assets	1,171
Other Compr. Net Income	0
Other Expenses	1,411
Other Liabilities	0
Other Net Income	2,635
Property and Equipment	1,660
Research and Development	38,845
Revenues	6,829
Selling, General and Administrative Expense	10,803

Output Variable	Value in 1000 USD
Assets	147,697
Liabilities	55,720
Expenses	51,059
Stockholders Equity	91,977
Net Income	-41,595
Comprehensive Net Income	-41,595
Economic Capital Ratio	-67%